<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0020117"><a href="http://purl.obolibrary.org/obo/MONDO_0020117">MONDO:0020117</a></h3>
<p><strong>Label:</strong> alpha granule disease</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0007686">MONDO:0007686</a> (gray platelet syndrome),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://purl.obolibrary.org/obo/OMIM_139090">OMIM:139090</a>, <a href="http://purl.obolibrary.org/obo/OMIM_187900">OMIM:187900</a>, <a href="http://www.orpha.net/ORDO/Orphanet_721">Orphanet:721</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0012147">HP:0012147</a> (Reduced quantity of Von Willebrand factor) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0100763">HP:0100763</a> (Abnormality of the lymphatic system) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0025408">HP:0025408</a> (Abnormal spleen morphology) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0025031">HP:0025031</a> (Abnormality of the digestive system) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0012823">HP:0012823</a> (Clinical modifier) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0012147">HP:0012147</a> (Reduced quantity of Von Willebrand factor) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0012145">HP:0012145</a> (Abnormality of multiple cell lineages in the bone marrow) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0011974">HP:0011974</a> (Myelofibrosis) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) and <a href="http://purl.obolibrary.org/obo/HP_0011872">HP:0011872</a> (Impaired thrombin-induced platelet aggregation) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0008320">HP:0008320</a> (Impaired collagen-induced platelet aggregation) and <a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0005561">HP:0005561</a> (Abnormality of bone marrow cell morphology) and <a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003679">HP:0003679</a> (Pace of progression) and <a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003676">HP:0003676</a> (Progressive) and <a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003271">HP:0003271</a> (Visceromegaly) and <a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) 66.67%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002715">HP:0002715</a> (Abnormality of the immune system) and <a href="http://purl.obolibrary.org/obo/HP_0008330">HP:0008330</a> (Reduced von Willebrand factor activity) 66.67%</li>
</ul>
</body>
</html>
